Webinar on Revolutionizing Oncology PLGA Polymer in Parenteral Formulation

Webinar on Revolutionizing Oncology PLGA Polymer in Parenteral Formulation

Dear, Webinar: "Revolutionizing Oncology: PLGA Polymer in Parenteral Formulation" is started now streaming live, so quickly join by following link. Here are the details: Date: 14th June 2024, Friday Time: 05:30 PM IST Time zone: Asia/Kolkata Duration: 45 min. Approximately Location: Online via Microsoft Teams Webinar Link details: Video call link: https://teams.microsoft.com/l/meetup-join/19%3ameeting_MjEyODUwM2UtMGZhOC00MjMzLTkzZTgtNjVkNmIzN2JmODJk%40thread.v2/0?context=%7b%22Tid%22%3a%22eaa4c627-401d-4de3-8219-0aa3598b98e6%22%2c%22Oid%22%3a%22705be9b2-cfc0-4ff3-9974-ffdef5740f96%22%7d Meeting ID: 466 217 267 12 Passcode: zkXxCS Thank you Nomisma Teams

Leuprolide Depot – Long-acting injectable formulation technologies

Leuprolide Depot – Long-acting injectable formulation technologies

Double Emulsion –solvent extraction
An aqueous solution of the peptide (which may contain excipients such as gelatin) is first emulsified in a polymer vehicle where the polyesters have been solubilized in an organic solvent (generally dichloromethane or ethyl acetate). This first emulsion is then poured into a second continuous aqueous phase containing a surfactant such as polyvinyl alcohol (PVA) from where the solvent will be extracted leading to the concomitant solidification of the microspheres.

Process limitations: Minimal solubility of the peptide in the organic solvent; shear stresses; the presence of residual solvent; the necessity of the aseptic process.

Example of manufactured product: Lupron Depot.

Nomisma`s Products for Lupron DepotDLG752A(PLGA 75:25)DL1002A(DL-PLA), and DL1003A(DL-PLA).